ROCHE POSICOR FIRST-LINE HYPERTENSION/ANGINA USE CLEARS FDA ADVISORY CMTE. WITH PRECAUTIONS ABOUT ECG CHANGES; POSICOR CHF TRIAL TO CONCLUDE IN MID-1998
Roche's Posicor (mibefradil) has a "success rate" in reducing blood pressure below 90 mm Hg in about two-thirds of patients given the highest recommended dose, the company maintained before FDA's Cardiovascular & Renal Drugs Advisory Committee Feb. 28.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth